Morning Market Losers

shares slipped 38.25% to $5.44 after the company reported a Q3 loss of $0.15 per share on revenue of $20.80 million and issued sales forecast. Benchmark downgraded E2open from Buy to Hold and lowered price target to $6.00.

shares tumbled 37.82% to $6.42 after the company reported top-line results from its clinical trials in organ-impaired patients.

dropped 29.58% to $1.69 after the company priced 4.86 million share offering at $1.75 per share

dipped 23.46% to $5.35 after the company announced the pricing of 2 million share public offering of common stock at $5 per share.

shares declined 21.75% to $5.11 after the company priced 49 million share offering at $5 per share.

slipped 19.46% to $7.74. Argos Therapeutics said Phase 2 trial did not meet endpoints.

shares dropped 15.09% to $37.04 following updated net sales and earnings guidance for the nine weeks ended January 3, 2015.

shares declined 14.86% to $6.05 after the company reported financial results for its fiscal second quarter. Total revenue came in at $262.7 million, below estimates of $268.43 million. The company's diluted loss per share from continuing operations came in at $0.15, inline with expectations.

shares slipped 11.98% to $18.67 after the company

shares fell 10.09% to $27.97 after the company reported the pricing of 7.17 million shares at $29.90 per unit.

dropped 7.23% to $73.71 after the company reported financial results Thursday for the third quarter. Its net sales were around $2.943 billion, slightly below estimates of $2.97 billion The company's net earnings came in at $1.23 per diluted share, or $225.4 million.

shares fell 2.46% to $66.14 after the company announced Thursday that its comparable sales on an owned plus licensed basis rose by 2.7% in the months of November and December 2014 combined, versus the same period last year.